Complement gene variants determine the risk of immunoglobulin-associated MPGN and C3 glomerulopathy and predict long-term renal outcome

Molecular Immunology

Volumn 71, Issue , 2016, Pages 131-142

  Iatropoulos, Paraskevas ^a   Noris, Marina ^a   Mele, Caterina ^a   Piras, Rossella ^a   Valoti, Elisabetta ^a   Bresin, Elena ^a   Curreri, Manuela ^a   Mondo, Elena ^b   Zito, Anna ^a   Gamba, Sara ^a   Bettoni, Serena ^a   Murer, Luisa ^c   Fremeaux Bacchi, Veronique ^d   Vivarelli, Marina ^e   Emma, Francesco ^e   Daina, Erica ^a   Remuzzi, Giuseppe ^a,b,f  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b Azienda Ospedaliera Papa Giovanni XXIII   (Italy)

^c UNIVERSITY HOSPITAL OF PADOVA   (Italy)

^d HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^e BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^f UNIVERSITY OF MILAN   (Italy)

Author keywords

C3 glomerulonephritis; C3 glomerulopathy; Dense Deposit Disease; Membranoproliferative glomerulonephritis; Rare diseases

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; AUTOANTIBODY; CLASSICAL COMPLEMENT PATHWAY C3 C5 CONVERTASE; COMPLEMENT; COMPLEMENT COMPONENT C1Q; COMPLEMENT FACTOR H; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ECULIZUMAB; FIBRINOGEN; IMMUNOGLOBULIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN A1; IMMUNOGLOBULIN G2; IMMUNOGLOBULIN G3; IMMUNOGLOBULIN M; MEMBRANE COFACTOR PROTEIN; MYCOPHENOLIC ACID; NEPHRITIC FACTOR; STEROID; THROMBOMODULIN; THBD PROTEIN, HUMAN;

ADOLESCENT; ADULT; ARTICLE; AUTOIMMUNE DISEASE; BIOCHEMICAL ANALYSIS; CLINICAL FEATURE; COMPLEMENT ACTIVATION; COMPLEMENT ALTERNATIVE PATHWAY; COMPLEMENT C3 GLOMERULONEPHRITIS; COMPLEMENT DISORDER; CONTROLLED STUDY; DENSE DEPOSIT DISEASE; DRUG DOSE INTENSIFICATION; END STAGE RENAL DISEASE; FEMALE; GENE FREQUENCY; GENE MUTATION; GENETIC ASSOCIATION; GENETIC CORRELATION; GENETIC RISK; GENETIC SCREENING; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; IMMUNE COMPLEX NEPHRITIS; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MALE; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM; STEROID THERAPY; TREATMENT OUTCOME; YOUNG ADULT; CLASSIFICATION; FLUORESCENT ANTIBODY TECHNIQUE; GENETIC PREDISPOSITION; GENETIC VARIATION; GENETICS; HIGH THROUGHPUT SEQUENCING; KIDNEY FAILURE, CHRONIC; MULTIPLEX POLYMERASE CHAIN REACTION; PATHOLOGY; RISK FACTOR;

ADOLESCENT; COMPLEMENT C3 NEPHRITIC FACTOR; COMPLEMENT PATHWAY, ALTERNATIVE; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; GLOMERULONEPHRITIS, MEMBRANOPROLIFERATIVE; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; IMMUNOGLOBULINS; KIDNEY FAILURE, CHRONIC; MALE; MULTIPLEX POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS; THROMBOMODULIN; YOUNG ADULT;

EID: 84958237174     PISSN: 01615890     EISSN: 18729142     Source Type: Journal    
DOI: 10.1016/j.molimm.2016.01.010     Document Type: Article

References (44)

1. Abrera-Abeleda M.A., Nishimura C., Frees K., Jones M., Maga T., Katz L.M., Zhang Y., Smith R.J. Allelic variants of complement genes associated with dense deposit disease. J. Am. Soc. Nephrol. 2011, 22:1551-1559.
2. Bircan Z., Toprak D., Kilicaslan I., Solakoglu S., Uysal V., Ponard D., Turker G. Factor H deficiency and fibrillary glomerulopathy. Nephrol. Dial. Transplant. 2004, 19:727-730.
3. Bomback A.S., Appel G.B. Pathogenesis of the C3 glomerulopathies and reclassification of MPGN. Nat. Rev. Nephrol. 2012, 8:634-642.
4. Bu F., Borsa N.G., Jones M.B., Takanami E., Nishimura C., Hauer J.J., Azaiez H., Black-Ziegelbein E.A., Meyer N.C., Kolbe D.L., Li Y., Frees K., Schnieders M.J., Thomas C., Nester C., Smith R.J. High-Throughput Genetic Testing for Thrombotic Microangiopathies and C3 Glomerulopathies. J. Am. Soc. Nephrol. 2015.
5. Cook H.T., Pickering M.C. Histopathology of MPGN and C3 glomerulopathies. Nat. Rev. Nephrol. 2015, 11:14-22.
6. Daina E., Noris M., Remuzzi G. Eculizumab in a patient with dense-deposit disease. N. Engl. J. Med. 2012, 366:1161-1163.
7. Delvaeye M., Noris M., De Vriese A., Esmon C.T., Esmon N.L., Ferrell G., Del-Favero J., Plaisance S., Claes B., Lambrechts D., Zoja C., Remuzzi G., Conway E.M. Thrombomodulin mutations in atypical hemolytic-uremic syndrome. N. Engl. J. Med. 2009, 361:345-357.
8. Dragon-Durey M.A., Fremeaux-Bacchi V., Loirat C., Blouin J., Niaudet P., Deschenes G., Coppo P., Herman Fridman W., Weiss L. Heterozygous and homozygous factor h deficiencies associated with hemolytic uremic syndrome or membranoproliferative glomerulonephritis: report and genetic analysis of 16 cases. J. Am. Soc. Nephrol. 2004, 15:787-795.
9. Fakhouri F., Fremeaux-Bacchi V., Noel L.H., Cook H.T., Pickering M.C. C3 glomerulopathy: a new classification. Nat. Rev. Nephrol. 2010, 6:494-499.
10. Forneris F., Ricklin D., Wu J., Tzekou A., Wallace R.S., Lambris J.D., Gros P. Structures of C3b in complex with factors B and D give insight into complement convertase formation. Science 2010, 330:1816-1820.
11. Fremeaux-Bacchi V., Weiss L., Brun P., Kazatchkine M.D. Selective disappearance of C3NeF IgG autoantibody in the plasma of a patient with membranoproliferative glomerulonephritis following renal transplantation. Nephrol. Dial. Transplant. 1994, 9:811-814.
12. Goodship T.H., Pappworth I.Y., Toth T., Denton M., Houlberg K., McCormick F., Warland D., Moore I., Hunze E.M., Staniforth S.J., Hayes C., Cavalcante D.P., Kavanagh D., Strain L., Herbert A.P., Schmidt C.Q., Barlow P.N., Harris C.L., Marchbank K.J. Factor H autoantibodies in membranoproliferative glomerulonephritis. Mol. Immunol. 2012, 52:200-206.
13. Hou J., Markowitz G.S., Bomback A.S., Appel G.B., Herlitz L.C., Barry Stokes M., D'Agati V.D. Toward a working definition of C3 glomerulopathy by immunofluorescence. Kidney Int. 2014, 85:450-456.
14. Imamura H., Konomoto T., Tanaka E., Hisano S., Yoshida Y., Fujimura Y., Miyata T., Nunoi H. Familial C3 glomerulonephritis associated with mutations in the gene for complement factor B. Nephrol. Dial. Transplant. 2015, 30:862-864.
15. Iwata K., Seya T., Yanagi Y., Pesando J.M., Johnson P.M., Okabe M., Ueda S., Ariga H., Nagasawa S. Diversity of sites for measles virus binding and for inactivation of complement C3b and C4b on membrane cofactor protein CD46. J. Biol. Chem. 1995, 270:15148-15152.
16. Jozsi M., Tortajada A., Uzonyi B., Goicoechea de Jorge E., Rodriguez de Cordoba S. Factor H-related proteins determine complement-activating surfaces. Trends Immunol. 2015, 36:374-384.
17. Kavanagh D., Goodship T.H., Richards A. Atypical hemolytic uremic syndrome. Semin. Nephrol. 2013, 33:508-530.
18. Little M.A., Dupont P., Campbell E., Dorman A., Walshe J.J. Severity of primary MPGN rather than MPGN type, determines renal survival and post-transplantation recurrence risk. Kidney Int. 2006, 69:504-511.
19. Maga T.K., Nishimura C.J., Weaver A.E., Frees K.L., Smith R.J. Mutations in alternative pathway complement proteins in American patients with atypical hemolytic uremic syndrome. Hum. Mutat. 2010, 31:E1445-1460.
20. Manenti L., Gnappi E., Vaglio A., Allegri L., Noris M., Bresin E., Pilato F.P., Valoti E., Pasquali S., Buzio C. Atypical haemolytic uraemic syndrome with underlying glomerulopathies. A case series and a review of the literature. Nephrol. Dial. Transplant. 2013, 28:2246-2259.
21. Martinez-Barricarte R., Heurich M., Valdes-Canedo F., Vazquez-Martul E., Torreira E., Montes T., Tortajada A., Pinto S., Lopez-Trascasa M., Morgan B.P., Llorca O., Harris C.L., Rodriguez de Cordoba S. Human C3 mutation reveals a mechanism of dense deposit disease pathogenesis and provides insights into complement activation and regulation. J. Clin. Invest. 2010, 120:3702-3712.
22. Medjeral-Thomas N.R., O'Shaughnessy M.M., O'Regan J.A., Traynor C., Flanagan M., Wong L., Teoh C.W., Awan A., Waldron M., Cairns T., O'Kelly P., Dorman A.M., Pickering M.C., Conlon P.J., Cook H.T. C3 glomerulopathy: clinicopathologic features and predictors of outcome. Clin. J. Am. Soc. Nephrol. 2014, 9:46-53.
23. Mizutani M., Yuzawa Y., Maruyama I., Sakamoto N., Matsuo S. Glomerular localization of thrombomodulin in human glomerulonephritis. Lab. Invest. 1993, 69:193-202.
24. Niemir Z.I., Kubiak A., Olejniczak P., Nowak A., Czekalski S. Can von Willebrand factor, platelet-endothelial cell adhesion molecule-1 and thrombomodulin be used as alternative markers of endothelial cell injury in human glomerulonephritis?. Rocz. Akad. Med. Bialymst 2004, 49:213-218.
25. Nilsson S.C., Nita I., Mansson L., Groeneveld T.W., Trouw L.A., Villoutreix B.O., Blom A.M. Analysis of binding sites on complement factor I that are required for its activity. J. Biol. Chem. 2010, 285:6235-6245.
26. Noris M., Remuzzi G. Glomerular Diseases Dependent on Complement Activation, Including Atypical Hemolytic Uremic Syndrome, Membranoproliferative Glomerulonephritis, and C3 Glomerulopathy: Core Curriculum 2015. Am. J. Kidney Dis. 2015, 66:359-375.
27. Noris M., Caprioli J., Bresin E., Mossali C., Pianetti G., Gamba S., Daina E., Fenili C., Castelletti F., Sorosina A., Piras R., Donadelli R., Maranta R., van der Meer I., Conway E.M., Zipfel P.F., Goodship T.H., Remuzzi G. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin. J. Am. Soc. Nephrol. 2010, 5:1844-1859.
28. Noris M., Galbusera M., Gastoldi S., Macor P., Banterla F., Bresin E., Tripodo C., Bettoni S., Donadelli R., Valoti E., Tedesco F., Amore A., Coppo R., Ruggenenti P., Gotti E., Remuzzi G. Dynamics of complement activation in aHUS and how to monitor eculizumab therapy. Blood 2014, 124:1715-1726.
29. Perez-Caballero D., Gonzalez-Rubio C., Gallardo M.E., Vera M., Lopez-Trascasa M., Rodriguez de Cordoba S., Sanchez-Corral P. Clustering of missense mutations in the C-terminal region of factor H in atypical hemolytic uremic syndrome. Am. J. Hum. Genet. 2001, 68:478-484.
30. Pickering M.C., de Jorge E.G., Martinez-Barricarte R., Recalde S., Garcia-Layana A., Rose K.L., Moss J., Walport M.J., Cook H.T., de Cordoba S.R., Botto M. Spontaneous hemolytic uremic syndrome triggered by complement factor H lacking surface recognition domains. J. Exp. Med. 2007, 204:1249-1256.
31. Pickering M.C., D'Agati V.D., Nester C.M., Smith R.J., Haas M., Appel G.B., Alpers C.E., Bajema I.M., Bedrosian C., Braun M., Doyle M., Fakhouri F., Fervenza F.C., Fogo A.B., Fremeaux-Bacchi V., Gale D.P., Goicoechea de Jorge E., Griffin G., Harris C.L., Holers V.M., Johnson S., Lavin P.J., Medjeral-Thomas N., Paul Morgan B., Nast C.C., Noel L.H., Peters D.K., Rodriguez de Cordoba S., Servais A., Sethi S., Song W.C., Tamburini P., Thurman J.M., Zavros M., Cook H.T. C3 glomerulopathy: consensus report. Kidney Int. 2013, 84:1079-1089.
32. Rooijakkers S.H., Wu J., Ruyken M., van Domselaar R., Planken K.L., Tzekou A., Ricklin D., Lambris J.D., Janssen B.J., van Strijp J.A., Gros P. Structural and functional implications of the alternative complement pathway C3 convertase stabilized by a staphylococcal inhibitor. Nat. Immunol. 2009, 10:721-727.
33. Schramm E.C., Roumenina L.T., Rybkine T., Chauvet S., Vieira-Martins P., Hue C., Maga T., Valoti E., Wilson V., Jokiranta S., Smith R.J., Noris M., Goodship T., Atkinson J.P., Fremeaux-Bacchi V. Functional mapping of the interactions between complement C3 and regulatory proteins using atypical hemolytic uremic syndrome-associated mutations. Blood 2015.
34. Servais A., Noel L.H., Roumenina L.T., Le Quintrec M., Ngo S., Dragon-Durey M.A., Macher M.A., Zuber J., Karras A., Provot F., Moulin B., Grunfeld J.P., Niaudet P., Lesavre P., Fremeaux-Bacchi V. Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies. Kidney Int 2012, 82:454-464.
35. Sethi S., Fervenza F.C. Membranoproliferative glomerulonephritis: pathogenetic heterogeneity and proposal for a new classification. Semin. Nephrol. 2011, 31:341-348.
36. Sethi S., Fervenza F.C. Membranoproliferative glomerulonephritis-a new look at an old entity. N. Engl. J. Med. 2012, 366:1119-1131.
37. Sethi S., Smith R.J., Dillon J.J., Fervenza F.C. C3 glomerulonephritis associated with complement factor B mutation. Am. J. Kidney Dis. 2015, 65:520-521.
38. Sprague S., Matta J.M., Bhandari M., Dodgin D., Clark C.R., Kregor P., Bradley G., Little L. Multicenter collaboration in observational research: improving generalizability and efficiency. J. Bone Joint. Surg. Am. 2009, 91(Suppl. 3):80-86.
39. Strobel S., Zimmering M., Papp K., Prechl J., Jozsi M. Anti-factor B autoantibody in dense deposit disease. Mol. Immunol. 2010, 47:1476-1483.
40. Strom C.M., Rivera S., Elzinga C., Angeloni T., Rosenthal S.H., Goos-Root D., Siaw M., Platt J., Braastadt C., Cheng L., Ross D., Sun W. Development and Validation of a Next-Generation Sequencing Assay for BRCA1 and BRCA2 Variants for the Clinical Laboratory. PLoS One 2015, 10:e0136419.
41. Tortajada A., Montes T., Martinez-Barricarte R., Morgan B.P., Harris C.L., de Cordoba S.R. The disease-protective complement factor H allotypic variant Ile62 shows increased binding affinity for C3b and enhanced cofactor activity. Hum. Mol. Genet. 2009, 18:3452-3461.
42. Van de Wouwer M., Collen D., Conway E.M. Thrombomodulin-protein C-EPCR system: integrated to regulate coagulation and inflammation. Arterioscler. Thromb. Vasc. Biol. 2004, 24:1374-1383.
43. Wu J., Wu Y.Q., Ricklin D., Janssen B.J., Lambris J.D., Gros P. Structure of complement fragment C3b-factor H and implications for host protection by complement regulators. Nat. Immunol. 2009, 10:728-733.
44. Zhang Y., Meyer N.C., Wang K., Nishimura C., Frees K., Jones M., Katz L.M., Sethi S., Smith R.J. Causes of alternative pathway dysregulation in dense deposit disease. Clin. J. Am. Soc. Nephrol. 2012, 7:265-274.